Beta-lapachone suppresses non-small cell lung cancer proliferation through the regulation of specificity protein 1

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 9, 2015, Pages 1302-1308

  Jeon, Young Joo ^a   Bang, Woong ^a   Choi, Yung Hyun ^b   Shim, Jung Hyun ^c   Chae, Jung Il ^a  

^a Chonbuk National University   (South Korea)

^b Dong Eui University   (South Korea)

^c Mokpo National University   (South Korea)

Author keywords

Apoptosis; Non small cell lung cancer; Specificity protein 1; lapachone

Indexed keywords

BETA LAPACHONE; TRANSCRIPTION FACTOR SP1; ANTINEOPLASTIC AGENT; BETA-LAPACHONE; NAPHTHOQUINONE; SP1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; H1299 CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; NCI H358 CELL LINE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DRUG EFFECTS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LUNG NEOPLASMS; NAPHTHOQUINONES; SP1 TRANSCRIPTION FACTOR;

EID: 84941061402     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00159     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66 (2007).
2. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol., 12, 175-180 (2011).
3. Wang L, Xiong Y, Sun Y, Fang Z, Li L, Ji H, Shi T. HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res., 38, D665-D669 (2010).
4. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov. Med., 13, 287-297 (2012).
5. Fruh M. The search for improved systemic therapy of non-small cell lung cancer-what are today's options? Lung Cancer, 72, 265-270 (2011).
6. Schaffner-Sabba K, Schmidt-Ruppin KH, Wehrli W, Schuerch AR, Wasley JW. β-Lapachone: synthesis of derivatives and activities in tumor models. J. Med. Chem., 27, 990-994 (1984).
7. Moon DO, Kang CH, Kim MO, Jeon YJ, Lee JD, Choi YH, Kim GY. β-Lapachone (LAPA) decreases cell viability and telomerase activity in leukemia cells: suppression of telomerase activity by LAPA. J. Med. Food, 13, 481-488 (2010).
8. Ferreira SB, Salomao K, de Carvalho da Silva F, Pinto AV, Kaiser CR, Pinto AC, Ferreira VF, de Castro SL. Synthesis and anti-Trypanosoma cruzi activity of beta-lapachone analogues. Eur. J. Med. Chem., 46, 3071-3077 (2011).
9. de Almeida ER, da Silva Filho AA, dos Santos ER, Lopes CA. Antiinflammatory action of lapachol. J. Ethnopharmacol., 29, 239-241 (1990).
10. Tzeng HP, Ho FM, Chao KF, Kuo ML, Lin-Shiau SY, Liu SH. β-Lapachone reduces endotoxin-induced macrophage activation and lung edema and mortality. Am. J. Respir. Crit. Care Med., 168, 85-91 (2003).
11. Guiraud P, Steiman R, Campos-Takaki GM, Seigle-Murandi F, Simeon de Buochberg M. Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. Planta Med., 60, 373-374 (1994).
12. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc. Natl. Acad. Sci. U.S.A., 90, 1839-1842 (1993).
13. Kung HN, Yang MJ, Chang CF, Chau YP, Lu KS. In vitro and in vivo wound healing-promoting activities of beta-lapachone. Am. J. Physiol. Cell Physiol., 295, C931-C943 (2008).
14. Frydman B, Marton LJ, Sun JS, Neder K, Witiak DT, Liu AA, Wang HM, Mao Y, Wu HY, Sanders MM, Liu LF. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones. Cancer Res., 57, 620-627 (1997).
15. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G, Boothman DA. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res., 55, 3706-3711 (1995).
16. Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA. β-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Exp. Cell Res., 267, 95-106 (2001).
17. Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene, 348, 1-11 (2005).
18. Deniaud E, Baguet J, Mathieu AL, Pages G, Marvel J, Leverrier Y. Overexpression of Sp1 transcription factor induces apoptosis. Onco gene, 25, 7096-7105 (2006).
19. Knappskog S, Lonning PE. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription, 2, 207-210 (2011).
20. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev., 29, 405-434 (2010).
21. Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, Burghardt R, Safe S. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp. Cell Res., 316, 2174-2188 (2010).
22. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer, 2, 143-148 (2002).
23. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P. Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and betalapachone. Int. J. Cancer, 73, 707-714 (1997).
24. Wuerzberger SM, Pink JJ, Planchon SM, Byers KL, Bornmann WG, Boothman DA. Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone. Cancer Res., 58, 1876-1885 (1998).
25. Choi YH, Kang HS, Yoo MA. Suppression of human prostate cancer cell growth by beta-lapachone via down-regulation of pRB phosphorylation and induction of Cdk inhibitor p21 (WAF1/CIP1). J. Biochem. Mol. Biol., 36, 223-229 (2003).
26. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur. J. Cancer, 41, 2438-2448 (2005).
27. Wang YT, Chuang JY, Shen MR, Yang WB, Chang WC, Hung JJ. Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J. Mol. Biol., 380, 869-885 (2008).
28. Chae JI, Jeon YJ, Shim JH. Anti-proliferative properties of kahweol in oral squamous cancer through the regulation specificity protein 1. Phytother. Res., 28, 1879-1886 (2014).
29. Kim DW, Ko SM, Jeon YJ, Noh YW, Choi NJ, Cho SD, Moon HS, Cho YS, Shin JC, Park SM, Seo KS, Choi JY, Chae JI, Shim JH. Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1. Int. J. Oncol., 43, 1103-1110 (2013).
30. Sun X, Ritzenthaler JD, Zhong X, Zheng Y, Roman J, Han S. Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha. Cancer Res., 69, 6445-6453 (2009).
31. Zheng Y, Ritzenthaler JD, Sun X, Roman J, Han S. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Res., 69, 896-904 (2009).
32. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest., 88, 1613-1621 (1991).
33. Chintharlapalli S, Papineni S, Lei P, Pathi S, Safe S. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer, 11, 371 (2011).
34. Pietrzak M, Puzianowska-Kuznicka M. p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. Biol. Chem., 389, 383-393 (2008).
35. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med., 1, 1052-1056 (1995).
36. Wang X, Gorospe M, Huang Y, Holbrook NJ. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene, 15, 2991-2997 (1997).
37. Ewen ME, Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol. Med., 10, 158-162 (2004).
38. Xu Q, Liu M, Xu N, Zhu H. Variation in Sp1 binding sites correlates with expression of survivin in breast cancer. Mol. Med. Rep., 10, 1395-1399 (2014).